News & Updates
Filter by Specialty:
Old cardio drug pulls a surprise in DIGIT-HF trial
Adding the cardiac glycoside digitoxin to guideline-directed medical therapy (GDMT) improves clinical outcomes in patients with heart failure with reduced ejection fraction (HFrEF), as shown in the DIGIT-HF trial, which took over 10 years to complete due to funding constraints.
Old cardio drug pulls a surprise in DIGIT-HF trial
04 Oct 2025
Obesity, smoking tied to 5-FU-induced cardiotoxicity in cancer patients
Smoking, obesity, treatment duration, and pre-existing cardiac diseases may contribute to the development of cardiotoxicity among patients with cancer who are undergoing 5-fluorouracil (5-FU) chemotherapy, suggests a recent study.
Obesity, smoking tied to 5-FU-induced cardiotoxicity in cancer patients
29 Sep 2025
Semaglutide, dulaglutide help prevent cognitive decline in HF patients
Treatment with semaglutide and dulaglutide results in a significantly lower risk of adverse cognitive decline in patients with heart failure (HF), as shown by the results of a retrospective cohort study using real-world data.
Semaglutide, dulaglutide help prevent cognitive decline in HF patients
28 Sep 2025
Higher serum vitamin D levels may lower risks of death, CVD in psoriasis patients
Individuals with psoriasis may benefit from an increased level of serum 25-hydroxivitamin D (25[OH]D), which has shown an association with a reduced risk of overall mortality and cardiovascular disease (CVD) in a recent study.